Phio Pharmaceuticals (PHIO) to Receive $3.1M Gross Proceeds from Warrant Exercise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Intel shares fall as competitor reports record results
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
July 12, 2024 8:02 AM EDTMarlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 545,286 shares of common stock of the Company originally issued in February 2020 through December 2023, having exercise prices between $324.00 and $9.72 per share, at a reduced exercise price of $5.45 per share. The shares of common stock issuable upon... More



